Targets › HT1A
1 program from 1 company in 1 trial: 1 Phase 3; Psychiatry.
Open in Phaseline: the race on HT1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Reviva Pharmaceuticals | Brilaroxazine (RP5063) Dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist | DRD2, HT1A | Phase 3 | Schizophrenia | – |
Schizophrenia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.